You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Harvard Business School
Baxter
Moodys

Last Updated: April 9, 2020

DrugPatentWatch Database Preview

Rucaparib camsylate - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic sources for rucaparib camsylate and what is the scope of patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and sixty-five patent family members in fifty-three countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate
International Patents:265
US Patents:12
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 13
Clinical Trials: 5
DailyMed Link:rucaparib camsylate at DailyMed
Recent Clinical Trials for rucaparib camsylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Clovis Oncology, Inc.Phase 2
ImmunoGen, Inc.Phase 1
Ohio State University Comprehensive Cancer CenterPhase 1

See all rucaparib camsylate clinical trials

Pharmacology for rucaparib camsylate
Synonyms for rucaparib camsylate
[4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)phenyl]-N-methylmethanaminium [(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl]methanesulfonate
1327258-57-0
1859053-21-6
41AX9SJ8KO
8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2,ef][2]benzazepin-6-one (1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid
8-Fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6H-pyrrolo[4,3,2,ef][2]benzazepin-6-one(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonicacid
8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1)
8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1H-azepino[5,4,3-cd]indol-1-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate
AC-30110
AKOS032962880
BCP18101
Bicyclo(2.2.1)heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-, (1S,4R)-, compd. with 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6H-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1)
C0-338
CHEBI:134692
CHEMBL3833368
CO-338
CS-6939
D10982
EX-A3053
HMS3750O21
HY-102003
PF-1367338-BW
Q27258428
Rubraca (TN)
Rucaparib (Camsylate)
rucaparib camphorsulfonate
Rucaparib Camphosulfonate
Rucaparib camsylate (USAN)
Rucaparib camsylate, >=98% (HPLC)
SB16540
SCHEMBL17512178
UNII-41AX9SJ8KO

US Patents and Regulatory Information for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No   Start Trial   Start Trial   Start Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-002 Dec 19, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-003 May 1, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for rucaparib camsylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2534153 LUC00093 Luxembourg   Start Trial PRODUCT NAME: RUCAPARIB CAMSYLATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1250 20180529
1633724 PA2015016,C1633724 Lithuania   Start Trial PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
2534153 122018000131 Germany   Start Trial PRODUCT NAME: RUCAPARIB CAMSYLAT; REGISTRATION NO/DATE: EU/1/17/1250 20180524
2534153 CA 2018 00041 Denmark   Start Trial PRODUCT NAME: RUCAPARIB CAMSYLATE; REG. NO/DATE: EU/1/17/1250/001-003 20180529
1633724 PA2015016 Lithuania   Start Trial PRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Harvard Business School
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.